AR132199A1 - Formulaciones de vacunas a base de proteínas meningocócicas y métodos para su fabricación - Google Patents

Formulaciones de vacunas a base de proteínas meningocócicas y métodos para su fabricación

Info

Publication number
AR132199A1
AR132199A1 ARP240100707A ARP240100707A AR132199A1 AR 132199 A1 AR132199 A1 AR 132199A1 AR P240100707 A ARP240100707 A AR P240100707A AR P240100707 A ARP240100707 A AR P240100707A AR 132199 A1 AR132199 A1 AR 132199A1
Authority
AR
Argentina
Prior art keywords
fhbp
modified
protein
proteins
fusion
Prior art date
Application number
ARP240100707A
Other languages
English (en)
Spanish (es)
Inventor
Sambhaji Shankar Pisal
Dattatreya Sarma Annamraju
Rajeev Mhalasakant Dhere
Original Assignee
Serum Inst Of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Inst Of India Pvt Ltd filed Critical Serum Inst Of India Pvt Ltd
Publication of AR132199A1 publication Critical patent/AR132199A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP240100707A 2023-03-24 2024-03-25 Formulaciones de vacunas a base de proteínas meningocócicas y métodos para su fabricación AR132199A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN202321021121A IN202321021121A (enExample) 2023-03-24 2023-03-24

Publications (1)

Publication Number Publication Date
AR132199A1 true AR132199A1 (es) 2025-06-04

Family

ID=92903953

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240100707A AR132199A1 (es) 2023-03-24 2024-03-25 Formulaciones de vacunas a base de proteínas meningocócicas y métodos para su fabricación

Country Status (9)

Country Link
KR (1) KR20250166279A (enExample)
CN (1) CN121038809A (enExample)
AR (1) AR132199A1 (enExample)
AU (1) AU2024249503A1 (enExample)
IL (1) IL323559A (enExample)
IN (1) IN202321021121A (enExample)
MX (1) MX2025011286A (enExample)
TW (1) TW202444740A (enExample)
WO (1) WO2024201502A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119925588B (zh) * 2025-04-08 2025-07-01 北京华诺泰生物医药科技有限公司 基于gE/pORF7双抗原纳米晶与智能相变佐剂的重组带状疱疹疫苗
CN120227449A (zh) * 2025-05-21 2025-07-01 苏州聚微生物科技有限公司 B群脑膜炎球菌疫苗组合物及其制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012004275A2 (pt) * 2009-08-27 2016-11-16 Novartis Ag polipeptídios híbridos incluindo sequências meningocócicas de fhbp
WO2014145578A1 (en) * 2013-03-15 2014-09-18 The Children's Hospital Of Philadelphia Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
CN110804102B (zh) * 2019-11-08 2021-07-20 苏州微超生物科技有限公司 B群脑膜炎球菌疫苗及其制备方法与应用

Also Published As

Publication number Publication date
CN121038809A (zh) 2025-11-28
AU2024249503A1 (en) 2025-10-16
KR20250166279A (ko) 2025-11-27
IL323559A (en) 2025-11-01
TW202444740A (zh) 2024-11-16
WO2024201502A1 (en) 2024-10-03
MX2025011286A (es) 2025-11-03
IN202321021121A (enExample) 2024-04-19

Similar Documents

Publication Publication Date Title
AR132199A1 (es) Formulaciones de vacunas a base de proteínas meningocócicas y métodos para su fabricación
CA2187083C (fr) Fragment peptidique de la proteine g du virus respiratoire syncytial, agent immunogene, composition pharmaceutique le contenant et procede de preparation
ES2301181T3 (es) Mutantes nuevos de bacterias mucosas gram negativas y su aplicacion en vacunas.
ES2761693T3 (es) Composiciones y métodos para mejorar las respuestas inmunitarias a Eimeria
CN104955835B (zh) 促进抗原序列的李斯特菌表达的信号肽融合配偶体以及其制备和使用方法
US11759514B2 (en) Stabilized pre-fusion RSV F proteins
JP2011507523A (ja) 遺伝子改変した弱毒化水疱性口内炎ウイルス、組成物およびその使用方法
CN102037135A (zh) 增强对有鞭毛的细菌的免疫反应的组合物和方法
US12331085B2 (en) Methods and compositions related to the next generation vaccine
JP7206383B2 (ja) 異種スパイクタンパク質を有する４／９１ ｉｂｖワクチン
ES2642138T3 (es) Cepas de Bordetella pertussis modificadas
CN118853525B (zh) 经修饰的百日咳鲍特菌菌株
EP2853270B1 (en) Recombinant avian-infectious coryza vaccine and process for preparing same
EP4196158A1 (en) Salmonella vaccine for the treatment of coronavirus
US20250026793A1 (en) Chimeric betacoronavirus spike polypeptides
WO2003102170A1 (fr) Souches de bordetella rendues deficientes par attenuation genetique
US20250263447A1 (en) Ompa mutations enhance omv production in bordetella pertussis
EP1292333B1 (fr) Composition adjuvante comprenant la proteine fha ou un fragment de la proteine fha sous forme libre
CN116549627A (zh) 基于腺病毒载体的广谱新冠疫苗及其应用
CN115040644B (zh) 新冠肺炎重组狂犬病病毒载体疫苗
KR20080082883A (ko) 약독화된 보르데텔라 브론키셉티카 (ｂｂｓ) 균주 및 그의제조 방법, 그를 포함하는 면역원성 조성물 및 그를 이용한포유동물의 ｂｂｓ 감염증을 치료 또는 예방하는 방법
US20250302943A1 (en) Re-focusing protein booster immunization compositions and methods of use thereof
JPWO2021064050A5 (enExample)
WO2024105539A1 (en) Recombinant lsdv vectored bovine coronavirus antigen constructs
US20210290760A1 (en) Bacteriophage-Based Vaccines and Engineered Bacteriophage